VerbatimParliament, as it happens

Breast Cancer: Drugs

Asked by Steve DarlingLiberal DemocratDepartment of Health and Social CareTabled Answered 17 July 2026UIN 17825

The question

To ask the Secretary of State for Health and Social Care, what steps his department has taken to make the drug Enhertu available for people with secondary breast cancer in England, following the increase in NICE’s cost effectiveness thresholds in April 2026.

Answered by Preet Kaur Gill

Following the increase in the National Institute for Health and Care Excellence’s (NICE) cost-effectiveness thresholds in April 2026, NICE, NHS England, and the manufacturers have resumed discussions to explore whether a commercial offer can be agreed that would make Enhertu cost-effective for HER2-low metastatic or unresectable breast cancer.

NICE previously published guidance in July 2024 and did not recommend Enhertu for this indication because the cost-effectiveness estimates were above the acceptable range for National Health Service resources.

Those discussions are ongoing. NICE and NHS England remain committed to securing access to effective treatments where they represent value for NHS patients.

Verbatim has judged this answer against the question that was actually asked — answered, partly answered, or evaded. Sign in to see the verdict →

Open this question in Verbatim →

Every written question, searchable

155,000 questions tabled since the election, with the answer each department gave — and the ones still unanswered, with the clock running. Free to search.

Search written questions →Read on Verbatim